PHP
ESPR

Parkman Healthcare Partners’s Esperion Therapeutics ESPR Stock Holding History

Parkman Healthcare Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-903,140
Closed -$1.49M – 97
2024
Q3 		$1.49M Sell
903,140
-241,506
-21% -$488K 0.19% 82
2024
Q2 		$2.54M Buy
1,144,646
+1,749
+0.2% +$4.11K 0.34% 70
2024
Q1 		$3.06M Sell
1,142,897
-282,307
-20% -$686K 0.38% 71
2023
Q4 		$4.26M Sell
1,425,204
-571,867
-29% -$742K 0.6% 54
2023
Q3 		$1.96M Sell
1,997,071
-135,238
-6% -$196K 0.36% 75
2023
Q2 		$2.96M Buy
2,132,309
+253,452
+13% +$354K 0.51% 59
2023
Q1 		$2.99M Buy
1,878,857
+1,056,073
+128% +$5.45M 0.65% 48
2022
Q4 		$5.13M Buy
822,784
+526,403
+178% +$3.76M 1.36% 25
2022
Q3 		$1.99M Buy
+296,381
New +$2.04M 0.56% 56

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Parkman Healthcare Partners's ESPR Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 903,140 shares — an estimated $1.49M sold.

Parkman Healthcare Partners first reported a position in ESPR in Q3 2022 and held it in 9 quarters. The position peaked at $5.13M in Q4 2022. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 903,140 Esperion Therapeutics shares in Q4 2024, an estimated $1.49M.
  • Parkman Healthcare Partners first reported a position in Esperion Therapeutics in Q3 2022 and held it in 9 quarters.
  • Parkman Healthcare Partners's Esperion Therapeutics position peaked at $5.13M in Q4 2022.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.